BIT's 16th Annual Congress of International Drug Discovery Science & Technology-China 2018
★ Scientific Program

BIT's 16th Annual World Congress of

Drug Discovery Science & Technology - Jinan 2018

Theme: Focusing on Biomedical Frontiers, Driving Industrial Innovative Development

Time: November 6-8, 2018

Place: Jinan, China

Preliminary Scientific Program

 

Session times on those days will not be finalized until the overall program schedule is completed.

Program Sessions (Please click each Forum for detailed program information)

Stream 1: Masters' Mind Honor Hall

Stream 2: High-end Dialogue

Stream 3: Breaking Research of Drug Discovery

Stream 4: New Drug R & D for Major Diseases

Stream 5: Industrial Art Gallery

Stream 6: Young Pharmacists’ Nexus

Stream 7: Projects Matchmaking

 

Stream 5: Translational Medicine, Clinical Trials, Drug Administrative Approval, and Market Development
Time: 13:30-15:15, Nov. 7, 2018
Place: Han Room, 1st Floor, Sheraton Jinan Hotel, Jinan, China

Chair

Dr. King C. Lee, Professor, Quinnipiac University, USA

13:30-13:35

Chair's Introduction

13:35-13:55

Title: Challenges and Solutions in Clinical Research
Dr. Hakim Mohamed, President and CEO, Once Source Clinical & Management, USA

13:55-14:15

Title: Approval of Pharma/Biologic Products in US-What Can a Small Startup Chinese Company Do?
Dr. King C. Lee, Professor, Quinnipiac University, USA

14:15-14:35

Title: Strategies for Obtaining Patents on Biomedical Inventions in the United States with a View to Successfully Withstand Critical Scrutiny by the Federal Courts and the Patent Trial and Appeal Board of the USPTO for their Validity and Enforceability
Dr. Xavier Pillai, Shareholder, Leydig, Voit & Mayer, Ltd., USA

14:35-14:55

Title: Translational Medicine: Use of Human Disease Models in Early Clinical Development
Dr. John Lambert, Corporate Vice President and Chief Medical Officer, PAREXEL International Shanghai, China

14:55-15:15 Title: GXP (GCP/ GLP/ GMP) Challenges in Drug Development
Dr. Frank Cheng, CEO and Senior Consultant, NovoScience Consulting Hong Kong, China

News Release
Full Program Released 说明: http://www.bitcongress.com/nano2018/images/NEW015.gif
● Call for Supporting Organizations and Media Partners
● Call for Session Chairs and Speakers 
● Call for Exhibitors and Sponsors
Hosting Organizations

Information Research Center of International Talent, SAFEA


Jinan Innovation Zone
Supporting Organizations


Ji'nan Branch of China Council for The Promotion of International Trade


University of South Australia



School of Biological Engineering, Qilu University of Technology

Operating Organizations
Official Travel Agency
Exhibition
Participating Organizations

Amgen, Inc.
Arrowhead Pharmaceuticals Inc.
Eisai Co., Ltd.
ChemDiv, Inc.
University of Queensland
Comenius University
Fountain Medical Development Ltd.,
McGill University
Pharmaron Inc.
Pfizer Inc.
Florida State University
Shanghai Jiaotong University School of Medicine
Leydig, Voit & Mayer, Ltd.
University of Pittsburgh
F. Hoffmann-La Roche
Tactical Therapeutics, Inc.
Leadscope Inc.
AbbVie Deutschland GmbH & Co. KG
Merck KGaA
Genentech, Inc.
Sanofi
Hamamatsu Photonics K.K.
University of Arizona
ChemDiv, Inc
AbMax Biotechnology Inc.
University Hospital Brno and Medical Faculty of Masaryk University
PSMMC, Riyadh
Boehringer Ingelheim Pharma GmbH & Co. KG
Global PKPD & Pharmacometrics, Eli Lilly and Company
Beijing Institute of Pharmacology and Toxicology
Auckland UniVersity
Cyclenium Pharma Inc.
Helmholtz Centre for Infection Research
University of Arizona
Medlab Clinical Pty Ltd.
National Institute of Biological Sciences, Beijing
Quinnipiac University/King Lee PhD, LCC
Novartis Institue of Biomedical Research
IriSys, LLC,
Private Clinic of Dermatovenerology Svidník
Saarland University
Cardiff University

Media Partners

BIT's Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609-826, Fax: 0086-411-84796897
Copyright © 2017-2018 BIT Congress Inc.